Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure

Author(s): Daniel Fabio Kawano*, Marcelo Rodrigues de Carvalho, Mauricio Ferreira Marcondes Machado, Adriana Karaoglanovic Carmona, Gilberto Ubida Leite Braga, Ivone Carvalho.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 17 , 2018

Submit Manuscript
Submit Proposal

Abstract:

Background: Fungal secondary metabolites are important sources for the discovery of new pharmaceuticals, as exemplified by penicillin, lovastatin and cyclosporine. Searching for secondary metabolites of the fungi Metarhizium spp., we previously identified tyrosine betaine as a major constituent.

Methods: Because of the structural similarity with other inhibitors of neprilysin (NEP), an enzyme explored for the treatment of heart failure, we devised the synthesis of tyrosine betaine and three analogues to be subjected to in vitro NEP inhibition assays and to molecular modeling studies.

Results: In spite of the similar binding modes with other NEP inhibitors, these compounds only displayed moderate inhibitory activities (IC50 ranging from 170.0 to 52.9 µM). However, they enclose structural features required to hinder passive blood brain barrier permeation (BBB).

Conclusions: Tyrosine betaine remains as a starting point for the development of NEP inhibitors because of the low probability of BBB permeation and, consequently, of NEP inhibition at the Central Nervous System, which is associated to an increment in the Aβ levels and, accordingly, with a higher risk for the onset of Alzheimer's disease.

Keywords: Neprilysin, heart failure, tyrosine betaine, fungal metabolites, Metarhizium spp, blood brain barrier.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 17
Year: 2018
Page: [1899 - 1904]
Pages: 6
DOI: 10.2174/1381612824666180515114236
Price: $58

Article Metrics

PDF: 15